American Journal of Cancer

, Volume 2, Issue 4, pp 245–253 | Cite as

Antisense Therapy

A New Approach to Cancer Treatment
Leading Article


The technique of gene silencing using antisense oligonucleotides is of high interest to investigators involved in drug development. In theory, this technology provides a means of specifically targeting the expression of a single gene product. The ever-expanding field of antisense technology now covers a wide range of substances including oligonucleotides, peptide nucleic acids as well as small interfering ribonucleic acids or RNA interference. Antisense technology has developed over the past decade to the stage where there are now several clinical trials evaluating the safety as well as efficacy of these agents in clinical oncology. With rapid developments in synthesis of the oligonucleotides, modifications that make the oligonucleotides more stable, and identification of more tumor-specific targets, it is likely that antisense oligonucleotides will become useful in cancer therapy. These drugs appear to be well tolerated and may be combined with conventional chemotherapeutic agents for better antitumor effects.


Docetaxel Mitoxantrone Antisense Oligonucleotide Peptide Nucleic Acid Hormone Refractory Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this manuscript. The author has no conflicts of interest that are directly relevant to the content of this manuscript.


  1. 1.
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–7PubMedCrossRefGoogle Scholar
  2. 2.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052–6PubMedCrossRefGoogle Scholar
  3. 3.
    Paterson BM, Roberts BE, Kuff EL. Structural gene identification and mapping by DNA-mRNA hybrid arrested cell free translation. Proc Natl Acad Sci U S A 1977; 74: 4370–4PubMedCrossRefGoogle Scholar
  4. 4.
    Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci U S A 1978; 75: 280–4PubMedCrossRefGoogle Scholar
  5. 5.
    Tamm I, Dorken B, Hartmann G. Antisense therapy in oncology: new hope for an old idea? Lancet 2001; 358: 489–97PubMedCrossRefGoogle Scholar
  6. 6.
    Lebedeva I, Stein CA. Antisense oligodeoxyribonucleotides in cancer: recent advances. BioDrugs 2000; 13: 195–216PubMedCrossRefGoogle Scholar
  7. 7.
    The Vitravene Study Group. A randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Opthalmol 2002; 133: 467–74CrossRefGoogle Scholar
  8. 8.
    The Vitravene Study Group. Safety of intravenous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Opthalmol 2002; 133: 484–98CrossRefGoogle Scholar
  9. 9.
    Crooke ST. Molecular mechanisms of action of antisense drugs. Biochim Biophys Acta 1999; 1489: 31–44PubMedCrossRefGoogle Scholar
  10. 10.
    Sarmiento UM, Perez JR, Becker JM, et al. In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res Dev 1994; 4: 99–107PubMedGoogle Scholar
  11. 11.
    Takei Y, Kodamatsu K, Itoh H, et al. 5′-,3′-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine: its design and application for cancer therapy. J Biol Chem 2002; 277: 23800–6PubMedCrossRefGoogle Scholar
  12. 12.
    Ratilainen T, Lincoln P, Norden B. A simple model for gene targeting. Biophys J 2001; 81: 2876–85PubMedCrossRefGoogle Scholar
  13. 13.
    Crooke ST. Oligonucleotide therapies. In: Wolff ME, editor. Burger’s medicinal chemistry and drug discovery. New York: Wiley and Sons, 1995: 863–900Google Scholar
  14. 14.
    Crooke ST. Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Dev 1998; 8: 133–4PubMedCrossRefGoogle Scholar
  15. 15.
    Dominski Z, Kole R. Restoration of correct splicing in thalassemic pre mRNA by antisense oligodeoxyribonucleotides. Proc Natl Acad Sci U S A 1993; 90: 8673–7PubMedCrossRefGoogle Scholar
  16. 16.
    Westermann P, Gross B, Hoinikis G. Inhibition of expression of SV40 virus large T antigen by antisense oligodeoxyribonucleotides. Biochim Biophys Acta 1989; 48: 85–93Google Scholar
  17. 17.
    Baker BF, Miraglia L, Hagedorn CH. Modulation of eukaryotic initiation factor —4E binding to 5′capped oligoribonucleotides by modified antisense oligodeoxyribonucleotides. J Biol Chem 1992; 267: 11495–9PubMedGoogle Scholar
  18. 18.
    Wu H, Macleod AR, Lima WF, et al. Identification and partial purification of human dopuble strand Rnase activity: a novel terminating mechanism for oligoribonucleotide antisense drugs. J Biol Chem 1998; 273: 2532–42PubMedCrossRefGoogle Scholar
  19. 19.
    Torrence PE, Xiao W, Li G, et al. recruiting the 2–5 A system for antisense therapeutics. Antisense Nucleic Acid Drug Dev 1997; 7: 203–6PubMedCrossRefGoogle Scholar
  20. 20.
    Wang S, Lee RJ, Cauchon G, et al. Delivery of antisense oligodeoxyribonucleotides against human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci U S A 1995; 92: 3318–22PubMedCrossRefGoogle Scholar
  21. 21.
    Zelphati O, Zon G, Leserman L. Inhibition of HIV-1 replication in cultured cells with antisense oligodeoxyribonucleotides encapsulated in immunoliposomes. Antisense Res Dev 1993; 3: 323–38PubMedGoogle Scholar
  22. 22.
    Midoux P, Mendes C, Legrand A, et al. Specific gene transfer mediated by lactosylated poly-L-lysine into hepatoma cells. Nucleic Acids Res 1993; 21: 871–8PubMedCrossRefGoogle Scholar
  23. 23.
    Zobel H-P, Kreuter J, Werner D, et al. Cationic polyhexylcyanoacrylate nanoparticles as carriers for antisense oligodeoxyribonucleotides. Antisense Res Dev 1997; 7: 483–93CrossRefGoogle Scholar
  24. 24.
    Schwab G, Chavany C, Duroux I, et al. Antisense oligodeoxyribonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated H-Ras mediated cell proliferation and tumorigenicity in nude rats. Proc Natl Acad Sci U S A 1994; 91: 10460–4PubMedCrossRefGoogle Scholar
  25. 25.
    Tondelli L, Ricca A, Laus M, et al. Highly efficient cellular uptake of c-myb antisense oligodeoxyribonucleotides through specifically designed polymeric nanospheres. Nucleic Acids Res 1998; 26: 5425–31PubMedCrossRefGoogle Scholar
  26. 26.
    Maruyama A, Ishihara T, Kim JS, et al. Nanoparticle DNA carrier with poly (L-lysine) grafted polysaccharide copolymer and poly(D,L-lactic acid). Bioconjug Chem 1997; 8: 735–42PubMedCrossRefGoogle Scholar
  27. 27.
    Vinogradov S, Bronich T, Kabanov AV. Self-assembly of polyaminepoly(ehtylene glycol) copolymers with phosphorothioate oligodeoxyribonucleotides. Bioconjug Chem 1998; 9: 805–12PubMedCrossRefGoogle Scholar
  28. 28.
    King HC, Sinha AA. Gene expression profile analysis by DNA microarrays: promise and pitfalls. JAMA 2001; 286: 2280–8PubMedCrossRefGoogle Scholar
  29. 29.
    Tu G, Cao Q, Zhou F, et al. Tetranucleotide GGGA motif in primary RNA transcripts. J Biol Chem 1998; 273: 25125–31PubMedCrossRefGoogle Scholar
  30. 30.
    Guvakova MA, Yakubov LA, Vlodavsky I, et al. Phosphorothioate oligodeoxyribonucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 1995; 270: 2620–7PubMedCrossRefGoogle Scholar
  31. 31.
    Perez JR, Li Y, Stein CA, et al. Sequence independent induction of Sp1 transcription factor activity by phosphorothioate oligodeoxynucleotides. Proc Natl Acad Sci U S A 1994; 91: 5957–61PubMedCrossRefGoogle Scholar
  32. 32.
    Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709–60PubMedCrossRefGoogle Scholar
  33. 33.
    McCluskie MJ, Weeratna RD, Davis HL. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants. Vaccine 2001; 19: 2657–60PubMedCrossRefGoogle Scholar
  34. 34.
    Kandimalla ER, Yu D, Agrawal S. Towards optimal design of second generation of immunomodulatory oligonucleotides. Curr Opin Mol Ther 2002; 4: 122–9PubMedGoogle Scholar
  35. 35.
    Teasdale RM, Matson SJ, Fisher E, et al. Inhibition of T4 polynucleotide kinase activity by phosphorothioate and chimeric oligodeoxynucleotides. Antisense Res Dev 1994; 4: 295–7PubMedGoogle Scholar
  36. 36.
    Benimetskaya L, Loike JD, Khaled Z, et al. Mac-1 (CD11b-CD18) is an oligodeoxynucleotide-binding protein. Nat Med 1997; 3: 414–20PubMedCrossRefGoogle Scholar
  37. 37.
    Jensen KK, Orum H, Nielsen PE, et al. Kinetics for hybridization of peptide nucleic acids (PNA) with DNA and RNA studied with the BIAcore technique. Biochemistry 1997; 36: 5072–7PubMedCrossRefGoogle Scholar
  38. 38.
    Braasch DW, Corey DR. Novel antisense and peptide nucleic strategies for controlling gene expression. Biochemistry 2002; 41: 4503–10PubMedCrossRefGoogle Scholar
  39. 39.
    Jabs DA, Griffiths PD. Fomivirsen for the treatment of cytomegalovirus retinitis. Am J Opthalmol 2002; 133: 552–6CrossRefGoogle Scholar
  40. 40.
    Martin DF, Kuppermann BD, Wolitz RA, et al. Oral gancilcovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. N Engl J Med 1999; 340: 1063–70PubMedCrossRefGoogle Scholar
  41. 41.
    Reed JC, Stein CA, Subasinge C, et al. Antisense mediated inhibition of BCL-2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxunucleotides. Cancer Res 1990; 50: 6565–70PubMedGoogle Scholar
  42. 42.
    Morris MJ, Tong WP, Cordon-Cardo C, et al. Phase 1 trial of Bcl-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. Clin Cancer Res 2002; 8: 679–83PubMedGoogle Scholar
  43. 43.
    Waters JS, Webb A, Cunningham D, et al. Phase 1 clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphoma. J Clin Oncol 2000; 18: 1812–23PubMedGoogle Scholar
  44. 44.
    Jansen B, Wacheck V, Heere-Reess E, et al. Chemosensitization of malignant mealanoma by BCL-2 antisense therapy. Lancet 2000; 356: 1728–33PubMedCrossRefGoogle Scholar
  45. 45.
    Chen HX, Marshall JL, Trocky N, et al. A phase 1 study of Bcl-2 antisense G3139 (GENTA) and weekly docetaxel in patients with advanced breast cancer and other solid tumors [abstract 692]. Proc Am Soc Clin Oncol 2000; 19: 178aGoogle Scholar
  46. 46.
    Tolcher AW. Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer [abstract]. Semin Oncol 2001 Aug 28; 4Suppl. 15: 67–70Google Scholar
  47. 47.
    Chi KN, Gleave ME, Klasa R, A phase 1 dose finding study of combined treatment with an antisense Bcl-2 oligonucleotide (G3139) and mitoxantrone in patinets with metastatic hormone refractory prostate cancer. Clin Cancer Res 2001; 7: 3920–7PubMedGoogle Scholar
  48. 48.
    National Cancer Institute (NCI). Docetaxel with or without oblimersen in treating patients with non-small cell lung cancer [online]. Available from URL: http:// [Accessed 2003 Jul 7]
  49. 49.
    Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small cell lung cancer. Ann Oncol 2002; 13: 539–45PubMedCrossRefGoogle Scholar
  50. 50.
    Yuen AR, Halsey J, Fisher GA, et al. Phase I study of an antisense oligonucleotide to protein kinase C-α(ISIS 3521/CGP 64128A) in patients with cancer. Clin Cancer Res 1999; 5: 3357–63PubMedGoogle Scholar
  51. 51.
    Mani S, Rudin CM, Kunkel K, et al. Phase I clinical and pharmacokinetic study of protein kinase C-α antisense oligonucleotide ISIS3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res 2002; 8: 1042–8PubMedGoogle Scholar
  52. 52.
    ISIS™ Pharmaceuticals. Enrollment is open for an investigational anti-cancer antisense drug: OGX-011 (ISIS 112989) [online]. Available from URL: http:// [Accessed 2003 Jul 7]
  53. 53.
    Wang H, Cai Q, Zeng X, et al. Antitumor activity and pharmacokinetics of a mixed backbone antisense oligonucleotide targeted to RI α subunit of protein kinase A after oral administration. Proc Natl Acad Sci U S A 1999; 96: 13989–94PubMedCrossRefGoogle Scholar
  54. 54.
    Siu LL, Gelmon KA, Moore MJ, et al. A phase I and pharmacokinetic (PK) study of the human DNA methyltransferase (Metase) antisense oligodeoxynucleotide MG98 given as a 21-day continuous infusion every 4 weeks [abstract 733]. Proc Am Soc Clin Oncol 2000; 19: 189aGoogle Scholar
  55. 55.
    Clark RE. Antisense therapeutics in chronic myeloid leukemia: the promise, the progress and the problems. Leukemia 2000; 14: 347–55PubMedCrossRefGoogle Scholar
  56. 56.
    Eder IE, Hoffmann J, Rogatsch H, et al. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther 2002; 9: 117–25PubMedCrossRefGoogle Scholar
  57. 57.
    Zhang Y, Lee HJ, Boado RJ, et al. Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med 2002; 4: 183–94PubMedCrossRefGoogle Scholar
  58. 58.
    Kinzel B, Hall J, Natt F, et al. Downregulation of Hus1 by antisense oligodeoxyribonucleotides enhances the sensitivity of human lung carcinoma cells to cisplatin. Cancer 2002; 94: 1808–14PubMedCrossRefGoogle Scholar
  59. 59.
    Fei R, Shaoyang L. Combination antigene therapy targeting c-myc and c-erbB2 in the ovarian cancer COC1 cell line. Gynecol Oncol 2002; 85: 40–4PubMedCrossRefGoogle Scholar
  60. 60.
    Taylor JK, Zhang QQ, Wyatt JR, et al. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol 1999; 17: 1097–100PubMedCrossRefGoogle Scholar
  61. 61.
    Derenne S, Monia B, Dean NM, et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-XL is an essential survival protein of human myeloma cells. Blood 2002; 100: 194–9PubMedCrossRefGoogle Scholar
  62. 62.
    Zamore PD. RNA interference: listening to the sound of silence. Nat Struct Biol 2001; 8: 746–50PubMedCrossRefGoogle Scholar
  63. 63.
    Donze O, Picard D. RNA interference in mammalian cells using siRNAs synthesized with T7polymerase. Nucleic Acids Res 2002; 30: e46PubMedCrossRefGoogle Scholar
  64. 64.
    Paul CP, Good PD, Winer I, et al. Effective expression of small interfering RNA in human cells. Nature Biotechnol 2002; 29: 505–8CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Department of Medicine and Pharmacology, Robert Wood Johnson Medical School, Cancer Institute of New JerseyUniversity of Medicine & Dentistry of New JerseyNew BrunswickUSA

Personalised recommendations